Investing Experience -
Risk Profile -
Followers
0
Following
0
Blog Posts
0
Threads
20
Blogs
Threads
Portfolio
Follower
Following
Summary
Total comments
20
Past 30 days
0
Past 7 days
0
Today
0
User Comments
Stock
Stock
Stock
2020-12-26 11:54 | Report Abuse
Nevertheless, the local market snapped its losing streak on Wednesday as bargain-hunting emerged ahead of the long weekend break, on the promising news of COVID-19 vaccine delivery by pharmaceutical company, AstraZeneca, which is expected to take place in the first half of 2021.
Stock
2020-12-26 11:51 | Report Abuse
Bursa expected to ride on Santa Claus rally next week December 26, 2020 10:28 am +08
KUALA LUMPUR (Dec 26): Bursa Malaysia is expected to rebound strongly next week, with the benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) set to test the psychological level of 1,700, amidst window-dressing activities and improved market sentiment.
Inter-Pacific Asset Management Sdn Bhd chief executive officer Datuk Dr Nazri Khan Adam Khan said the key index is poised to march into the new year on a high note, riding on the ‘Santa Claus’ rally as investors turn bullish towards year-end.
“Traditionally, the last week of December and the first week of new year are the strongest weeks of the year, therefore I believe KLCI will move higher between 1,680 and 1,700,” he told Bernama.
He said the market sentiment would be positive due to rising commodity prices, stronger ringgit versus the US dollar, optimism over COVID-19 vaccine distribution in Malaysia next year, as well as a smooth free trade deal between Britain and the European Union.
Nazri Khan said the overall market volume would be thin in the next two weeks as a majority of institutional buyers would be inactive due to the holidays, but the market momentum would be supported by buying in the small-capitalisation stocks.
Bursa Malaysia started the week on a weak note as investors’ sentiment was affected by worries over the global economy outlook, and the risk appetite continued to drift away the following day on mounting concerns over the new COVID-19 strain in the United Kingdom and the weak oil prices.
Nevertheless, the local market snapped its losing streak on Wednesday as bargain-hunting emerged ahead of the long weekend break, on the promising news of COVID-19 vaccine delivery by pharmaceutical company, AstraZeneca, which is expected to take place in the first half of 2021.
However, the FBM KLCI reversed its gains on Thursday due to profit taking amidst the cautious market sentiment, before taking a break for Christmas on Friday.
On a Friday-to-Thursday basis, the benchmark FBM KLCI decreased 11.32 points to 1,641.17 on Thursday from 1,652.49 on Friday last week.
On the scoreboard, the FBM Emas Index fell 79.57 points to 11,810.92, the FBMT 100 Index erased 80.12 points to 11,569.93, the FBM 70 contracted 106.06 points to 15,112.54, and the FBM Emas Shariah Index reduced 51.29 points to 13,283.18.
However, the FBM ACE Index surged 209.65 points to 10,657.3.
Sector-wise, the Plantation Index bagged 57.48 points to 7,407.28, the Industrial Products and Services Index added 0.2 of-a-point to 175.89, while the Financial Services Index tumbled 164.63 points to 15,260.37.
The Energy Index shed 28.58 points to 879.47, the Healthcare Index gave up 29.95 points for 3,672.36, while the Technology Index trimmed 0.46 of-a-point to 67.41.
Weekly turnover decreased sharply to 28.99 billion units worth RM14.05 billion from 50.37 billion units worth RM26.15 billion last week.
Main Market volume plummeted to 17.26 billion shares valued at RM10.7 billion versus 32.40 billion shares valued at RM22.03 billion previously.
Warrants turnover, however, increased to 7.85 billion units worth RM364.77 million from 4.97 billion units worth RM804.71 million in the previous week.
The ACE Market volume shrank to 9.52 billion shares valued at RM2.99 billion from 13.04 billion shares valued at RM3.31 billion previously.
Stock
2020-12-26 11:49 | Report Abuse
AstraZeneca in deal with Kangtai Bio to supply potential COVID-19 vaccine in China - BEIJING, Aug 6 (Reuters) - AstraZeneca PLC has signed an exclusive framework agreement with China’s Shenzhen Kangtai Biological Products to supply its COVID-19 vaccine candidate in mainland China, the British pharmaceutical giant said on Thursday.
To meet market demand in China, Shenzhen Kangtai is obliged to make sure it has an annual production capacity of at least 100 million doses of the experimental shot AZD1222, which AstraZeneca co-developed with researchers at Oxford University, by the end of this year, and a capacity of at least 200 million doses by the end of next year, AstraZeneca said in a statement on the Chinese social media site WeChat.
The two companies will also explore the possiblity of cooperation on the vaccine candidate in other markets, AstraZeneca said.
Stock
Stock
2020-08-03 21:44 | Report Abuse
Theedgemarkets.com
KUALA LUMPUR (July 21): Komarkcorp Bhd is set to diversify into the manufacture and sale of face masks, given the current market environment.
In a circular to shareholders today, Komarkcorp said it had on June 15 incorporated its unit Komark Mask (M) Sdn Bhd to carry out a new business which it said is anticipated to contribute 25% or more of the net profits of the group through manufacturing the commonly used three-ply surgical face masks and KN95 masks.
It said the new business will be led by an executive director of the company as well as its group chief operating officer Koh Chie Jooi.
Komarkcorp said it has experienced a declining trend in revenue and consecutive loss after tax since 2017.
The company, which is involved in printing of label and packaging solution, said it believes the new business will capitalise on a booming segment with favourable long-term prospects while making the most out of the opportunities created by the Covid-19 pandemic.
In this regard, Komarkcorp said it has targeted countries with high Covid-19 infection rates such as the US, European countries, Africa, South America and India as principal export markets for the new venture.
It will also provide an alternative source of income to the group’s current core business.
“Even assuming the discovery and worldwide distribution of a vaccine and or cure, there has been much heightened awareness built in the general public on the need for self-protection and therefore hygienic practices are expected to remain. Practices such as the use of face masks in public areas are expected to remain a new normal in our society to prevent a similar outbreak of another virus in the future,” it said.
The group intends to set up its production centre in one of its existing consumer packaging and printing factories located in Balakong, Selangor with 30 face mask production lines. Operation of the group’s existing consumer packaging and printing lines will remain unaffected.
“Moving forward, subject to the growth in demand for face masks, the group plans to gradually expand the production capacity of the new business over the course of 24 months by setting up to 30 production lines. This is estimated to achieve a yearly production capacity of approximately 522 million three-ply surgical face masks and 120 million KN95 face masks.”
Komarkcorp also announced a proposed private placement to issue up to 61.68 million new shares, to raise RM25.56 million and utilise up to RM17.9 million to fund its investment in the new business.
The group also announced the proposed establishment of an employees’ share options scheme (ESOS) involving up to 15% of the total number of issued shares of Komarkcorp.
It said the scheme should last for a five-year duration but is subject to extension as provided under the by-laws.
The exercise price will be determined by the ESOS committee and shall be conclusive and binding on the grantees, it noted.
At the midday break, Komarkcorp gained 1 sen or 2.06% to 50 sen, with a market capitalisation of RM100.74 million. The stock saw some 3.3 million shares traded.
Stock
2020-08-03 21:43 | Report Abuse
Theedgemarkets.com
KUALA LUMPUR (July 21): Komarkcorp Bhd is set to diversify into the manufacture and sale of face masks, given the current market environment.
In a circular to shareholders today, Komarkcorp said it had on June 15 incorporated its unit Komark Mask (M) Sdn Bhd to carry out a new business which it said is anticipated to contribute 25% or more of the net profits of the group through manufacturing the commonly used three-ply surgical face masks and KN95 masks.
It said the new business will be led by an executive director of the company as well as its group chief operating officer Koh Chie Jooi.
Komarkcorp said it has experienced a declining trend in revenue and consecutive loss after tax since 2017.
The company, which is involved in printing of label and packaging solution, said it believes the new business will capitalise on a booming segment with favourable long-term prospects while making the most out of the opportunities created by the Covid-19 pandemic.
In this regard, Komarkcorp said it has targeted countries with high Covid-19 infection rates such as the US, European countries, Africa, South America and India as principal export markets for the new venture.
It will also provide an alternative source of income to the group’s current core business.
“Even assuming the discovery and worldwide distribution of a vaccine and or cure, there has been much heightened awareness built in the general public on the need for self-protection and therefore hygienic practices are expected to remain. Practices such as the use of face masks in public areas are expected to remain a new normal in our society to prevent a similar outbreak of another virus in the future,” it said.
The group intends to set up its production centre in one of its existing consumer packaging and printing factories located in Balakong, Selangor with 30 face mask production lines. Operation of the group’s existing consumer packaging and printing lines will remain unaffected.
“Moving forward, subject to the growth in demand for face masks, the group plans to gradually expand the production capacity of the new business over the course of 24 months by setting up to 30 production lines. This is estimated to achieve a yearly production capacity of approximately 522 million three-ply surgical face masks and 120 million KN95 face masks.”
Komarkcorp also announced a proposed private placement to issue up to 61.68 million new shares, to raise RM25.56 million and utilise up to RM17.9 million to fund its investment in the new business.
The group also announced the proposed establishment of an employees’ share options scheme (ESOS) involving up to 15% of the total number of issued shares of Komarkcorp.
It said the scheme should last for a five-year duration but is subject to extension as provided under the by-laws.
The exercise price will be determined by the ESOS committee and shall be conclusive and binding on the grantees, it noted.
At the midday break, Komarkcorp gained 1 sen or 2.06% to 50 sen, with a market capitalisation of RM100.74 million. The stock saw some 3.3 million shares traded.
Stock
2020-08-03 21:43 | Report Abuse
Theedgemarkets.com
KUALA LUMPUR (July 21): Komarkcorp Bhd is set to diversify into the manufacture and sale of face masks, given the current market environment.
In a circular to shareholders today, Komarkcorp said it had on June 15 incorporated its unit Komark Mask (M) Sdn Bhd to carry out a new business which it said is anticipated to contribute 25% or more of the net profits of the group through manufacturing the commonly used three-ply surgical face masks and KN95 masks.
It said the new business will be led by an executive director of the company as well as its group chief operating officer Koh Chie Jooi.
Komarkcorp said it has experienced a declining trend in revenue and consecutive loss after tax since 2017.
The company, which is involved in printing of label and packaging solution, said it believes the new business will capitalise on a booming segment with favourable long-term prospects while making the most out of the opportunities created by the Covid-19 pandemic.
In this regard, Komarkcorp said it has targeted countries with high Covid-19 infection rates such as the US, European countries, Africa, South America and India as principal export markets for the new venture.
It will also provide an alternative source of income to the group’s current core business.
“Even assuming the discovery and worldwide distribution of a vaccine and or cure, there has been much heightened awareness built in the general public on the need for self-protection and therefore hygienic practices are expected to remain. Practices such as the use of face masks in public areas are expected to remain a new normal in our society to prevent a similar outbreak of another virus in the future,” it said.
The group intends to set up its production centre in one of its existing consumer packaging and printing factories located in Balakong, Selangor with 30 face mask production lines. Operation of the group’s existing consumer packaging and printing lines will remain unaffected.
“Moving forward, subject to the growth in demand for face masks, the group plans to gradually expand the production capacity of the new business over the course of 24 months by setting up to 30 production lines. This is estimated to achieve a yearly production capacity of approximately 522 million three-ply surgical face masks and 120 million KN95 face masks.”
Komarkcorp also announced a proposed private placement to issue up to 61.68 million new shares, to raise RM25.56 million and utilise up to RM17.9 million to fund its investment in the new business.
The group also announced the proposed establishment of an employees’ share options scheme (ESOS) involving up to 15% of the total number of issued shares of Komarkcorp.
It said the scheme should last for a five-year duration but is subject to extension as provided under the by-laws.
The exercise price will be determined by the ESOS committee and shall be conclusive and binding on the grantees, it noted.
At the midday break, Komarkcorp gained 1 sen or 2.06% to 50 sen, with a market capitalisation of RM100.74 million. The stock saw some 3.3 million shares traded.
Stock
2020-08-03 21:42 | Report Abuse
Theedgemarkets.com
KUALA LUMPUR (July 21): Komarkcorp Bhd is set to diversify into the manufacture and sale of face masks, given the current market environment.
In a circular to shareholders today, Komarkcorp said it had on June 15 incorporated its unit Komark Mask (M) Sdn Bhd to carry out a new business which it said is anticipated to contribute 25% or more of the net profits of the group through manufacturing the commonly used three-ply surgical face masks and KN95 masks.
It said the new business will be led by an executive director of the company as well as its group chief operating officer Koh Chie Jooi.
Komarkcorp said it has experienced a declining trend in revenue and consecutive loss after tax since 2017.
The company, which is involved in printing of label and packaging solution, said it believes the new business will capitalise on a booming segment with favourable long-term prospects while making the most out of the opportunities created by the Covid-19 pandemic.
In this regard, Komarkcorp said it has targeted countries with high Covid-19 infection rates such as the US, European countries, Africa, South America and India as principal export markets for the new venture.
It will also provide an alternative source of income to the group’s current core business.
“Even assuming the discovery and worldwide distribution of a vaccine and or cure, there has been much heightened awareness built in the general public on the need for self-protection and therefore hygienic practices are expected to remain. Practices such as the use of face masks in public areas are expected to remain a new normal in our society to prevent a similar outbreak of another virus in the future,” it said.
The group intends to set up its production centre in one of its existing consumer packaging and printing factories located in Balakong, Selangor with 30 face mask production lines. Operation of the group’s existing consumer packaging and printing lines will remain unaffected.
“Moving forward, subject to the growth in demand for face masks, the group plans to gradually expand the production capacity of the new business over the course of 24 months by setting up to 30 production lines. This is estimated to achieve a yearly production capacity of approximately 522 million three-ply surgical face masks and 120 million KN95 face masks.”
Komarkcorp also announced a proposed private placement to issue up to 61.68 million new shares, to raise RM25.56 million and utilise up to RM17.9 million to fund its investment in the new business.
The group also announced the proposed establishment of an employees’ share options scheme (ESOS) involving up to 15% of the total number of issued shares of Komarkcorp.
It said the scheme should last for a five-year duration but is subject to extension as provided under the by-laws.
The exercise price will be determined by the ESOS committee and shall be conclusive and binding on the grantees, it noted.
At the midday break, Komarkcorp gained 1 sen or 2.06% to 50 sen, with a market capitalisation of RM100.74 million. The stock saw some 3.3 million shares traded.
Stock
2020-08-03 21:42 | Report Abuse
Theedgemarkets.com
KUALA LUMPUR (July 21): Komarkcorp Bhd is set to diversify into the manufacture and sale of face masks, given the current market environment.
In a circular to shareholders today, Komarkcorp said it had on June 15 incorporated its unit Komark Mask (M) Sdn Bhd to carry out a new business which it said is anticipated to contribute 25% or more of the net profits of the group through manufacturing the commonly used three-ply surgical face masks and KN95 masks.
It said the new business will be led by an executive director of the company as well as its group chief operating officer Koh Chie Jooi.
Komarkcorp said it has experienced a declining trend in revenue and consecutive loss after tax since 2017.
The company, which is involved in printing of label and packaging solution, said it believes the new business will capitalise on a booming segment with favourable long-term prospects while making the most out of the opportunities created by the Covid-19 pandemic.
In this regard, Komarkcorp said it has targeted countries with high Covid-19 infection rates such as the US, European countries, Africa, South America and India as principal export markets for the new venture.
It will also provide an alternative source of income to the group’s current core business.
“Even assuming the discovery and worldwide distribution of a vaccine and or cure, there has been much heightened awareness built in the general public on the need for self-protection and therefore hygienic practices are expected to remain. Practices such as the use of face masks in public areas are expected to remain a new normal in our society to prevent a similar outbreak of another virus in the future,” it said.
The group intends to set up its production centre in one of its existing consumer packaging and printing factories located in Balakong, Selangor with 30 face mask production lines. Operation of the group’s existing consumer packaging and printing lines will remain unaffected.
“Moving forward, subject to the growth in demand for face masks, the group plans to gradually expand the production capacity of the new business over the course of 24 months by setting up to 30 production lines. This is estimated to achieve a yearly production capacity of approximately 522 million three-ply surgical face masks and 120 million KN95 face masks.”
Komarkcorp also announced a proposed private placement to issue up to 61.68 million new shares, to raise RM25.56 million and utilise up to RM17.9 million to fund its investment in the new business.
The group also announced the proposed establishment of an employees’ share options scheme (ESOS) involving up to 15% of the total number of issued shares of Komarkcorp.
It said the scheme should last for a five-year duration but is subject to extension as provided under the by-laws.
The exercise price will be determined by the ESOS committee and shall be conclusive and binding on the grantees, it noted.
At the midday break, Komarkcorp gained 1 sen or 2.06% to 50 sen, with a market capitalisation of RM100.74 million. The stock saw some 3.3 million shares traded.
Stock
2020-08-03 21:42 | Report Abuse
Theedgemarkets.com
KUALA LUMPUR (July 21): Komarkcorp Bhd is set to diversify into the manufacture and sale of face masks, given the current market environment.
In a circular to shareholders today, Komarkcorp said it had on June 15 incorporated its unit Komark Mask (M) Sdn Bhd to carry out a new business which it said is anticipated to contribute 25% or more of the net profits of the group through manufacturing the commonly used three-ply surgical face masks and KN95 masks.
It said the new business will be led by an executive director of the company as well as its group chief operating officer Koh Chie Jooi.
Komarkcorp said it has experienced a declining trend in revenue and consecutive loss after tax since 2017.
The company, which is involved in printing of label and packaging solution, said it believes the new business will capitalise on a booming segment with favourable long-term prospects while making the most out of the opportunities created by the Covid-19 pandemic.
In this regard, Komarkcorp said it has targeted countries with high Covid-19 infection rates such as the US, European countries, Africa, South America and India as principal export markets for the new venture.
It will also provide an alternative source of income to the group’s current core business.
“Even assuming the discovery and worldwide distribution of a vaccine and or cure, there has been much heightened awareness built in the general public on the need for self-protection and therefore hygienic practices are expected to remain. Practices such as the use of face masks in public areas are expected to remain a new normal in our society to prevent a similar outbreak of another virus in the future,” it said.
The group intends to set up its production centre in one of its existing consumer packaging and printing factories located in Balakong, Selangor with 30 face mask production lines. Operation of the group’s existing consumer packaging and printing lines will remain unaffected.
“Moving forward, subject to the growth in demand for face masks, the group plans to gradually expand the production capacity of the new business over the course of 24 months by setting up to 30 production lines. This is estimated to achieve a yearly production capacity of approximately 522 million three-ply surgical face masks and 120 million KN95 face masks.”
Komarkcorp also announced a proposed private placement to issue up to 61.68 million new shares, to raise RM25.56 million and utilise up to RM17.9 million to fund its investment in the new business.
The group also announced the proposed establishment of an employees’ share options scheme (ESOS) involving up to 15% of the total number of issued shares of Komarkcorp.
It said the scheme should last for a five-year duration but is subject to extension as provided under the by-laws.
The exercise price will be determined by the ESOS committee and shall be conclusive and binding on the grantees, it noted.
At the midday break, Komarkcorp gained 1 sen or 2.06% to 50 sen, with a market capitalisation of RM100.74 million. The stock saw some 3.3 million shares traded.
Stock
2020-08-03 21:41 | Report Abuse
Theedgemarkets.com
KUALA LUMPUR (July 21): Komarkcorp Bhd is set to diversify into the manufacture and sale of face masks, given the current market environment.
In a circular to shareholders today, Komarkcorp said it had on June 15 incorporated its unit Komark Mask (M) Sdn Bhd to carry out a new business which it said is anticipated to contribute 25% or more of the net profits of the group through manufacturing the commonly used three-ply surgical face masks and KN95 masks.
It said the new business will be led by an executive director of the company as well as its group chief operating officer Koh Chie Jooi.
Komarkcorp said it has experienced a declining trend in revenue and consecutive loss after tax since 2017.
The company, which is involved in printing of label and packaging solution, said it believes the new business will capitalise on a booming segment with favourable long-term prospects while making the most out of the opportunities created by the Covid-19 pandemic.
In this regard, Komarkcorp said it has targeted countries with high Covid-19 infection rates such as the US, European countries, Africa, South America and India as principal export markets for the new venture.
It will also provide an alternative source of income to the group’s current core business.
“Even assuming the discovery and worldwide distribution of a vaccine and or cure, there has been much heightened awareness built in the general public on the need for self-protection and therefore hygienic practices are expected to remain. Practices such as the use of face masks in public areas are expected to remain a new normal in our society to prevent a similar outbreak of another virus in the future,” it said.
The group intends to set up its production centre in one of its existing consumer packaging and printing factories located in Balakong, Selangor with 30 face mask production lines. Operation of the group’s existing consumer packaging and printing lines will remain unaffected.
“Moving forward, subject to the growth in demand for face masks, the group plans to gradually expand the production capacity of the new business over the course of 24 months by setting up to 30 production lines. This is estimated to achieve a yearly production capacity of approximately 522 million three-ply surgical face masks and 120 million KN95 face masks.”
Komarkcorp also announced a proposed private placement to issue up to 61.68 million new shares, to raise RM25.56 million and utilise up to RM17.9 million to fund its investment in the new business.
The group also announced the proposed establishment of an employees’ share options scheme (ESOS) involving up to 15% of the total number of issued shares of Komarkcorp.
It said the scheme should last for a five-year duration but is subject to extension as provided under the by-laws.
The exercise price will be determined by the ESOS committee and shall be conclusive and binding on the grantees, it noted.
At the midday break, Komarkcorp gained 1 sen or 2.06% to 50 sen, with a market capitalisation of RM100.74 million. The stock saw some 3.3 million shares traded.
Stock
2020-08-03 21:41 | Report Abuse
Theedgemarkets.com
KUALA LUMPUR (July 21): Komarkcorp Bhd is set to diversify into the manufacture and sale of face masks, given the current market environment.
In a circular to shareholders today, Komarkcorp said it had on June 15 incorporated its unit Komark Mask (M) Sdn Bhd to carry out a new business which it said is anticipated to contribute 25% or more of the net profits of the group through manufacturing the commonly used three-ply surgical face masks and KN95 masks.
It said the new business will be led by an executive director of the company as well as its group chief operating officer Koh Chie Jooi.
Komarkcorp said it has experienced a declining trend in revenue and consecutive loss after tax since 2017.
The company, which is involved in printing of label and packaging solution, said it believes the new business will capitalise on a booming segment with favourable long-term prospects while making the most out of the opportunities created by the Covid-19 pandemic.
In this regard, Komarkcorp said it has targeted countries with high Covid-19 infection rates such as the US, European countries, Africa, South America and India as principal export markets for the new venture.
It will also provide an alternative source of income to the group’s current core business.
“Even assuming the discovery and worldwide distribution of a vaccine and or cure, there has been much heightened awareness built in the general public on the need for self-protection and therefore hygienic practices are expected to remain. Practices such as the use of face masks in public areas are expected to remain a new normal in our society to prevent a similar outbreak of another virus in the future,” it said.
The group intends to set up its production centre in one of its existing consumer packaging and printing factories located in Balakong, Selangor with 30 face mask production lines. Operation of the group’s existing consumer packaging and printing lines will remain unaffected.
“Moving forward, subject to the growth in demand for face masks, the group plans to gradually expand the production capacity of the new business over the course of 24 months by setting up to 30 production lines. This is estimated to achieve a yearly production capacity of approximately 522 million three-ply surgical face masks and 120 million KN95 face masks.”
Komarkcorp also announced a proposed private placement to issue up to 61.68 million new shares, to raise RM25.56 million and utilise up to RM17.9 million to fund its investment in the new business.
The group also announced the proposed establishment of an employees’ share options scheme (ESOS) involving up to 15% of the total number of issued shares of Komarkcorp.
It said the scheme should last for a five-year duration but is subject to extension as provided under the by-laws.
The exercise price will be determined by the ESOS committee and shall be conclusive and binding on the grantees, it noted.
At the midday break, Komarkcorp gained 1 sen or 2.06% to 50 sen, with a market capitalisation of RM100.74 million. The stock saw some 3.3 million shares traded.
Stock
2020-06-26 21:06 | Report Abuse
Buaya asking to give out glove stocks and proposed to buy banking stocks (banking stocks will suffer at least for the next 2 qtr results.....but buaya asking to buy ....???) for sure they will let go all banking stocks and go buy glove stocks now :D
Stock
Stock
2020-06-26 20:55 | Report Abuse
Buaya asking to give out glove stocks and proposed to buy banking stocks (banking stocks will suffer at least for the next 2 qtr results.....but buaya asking to buy ....???) for sure they will let go all banking stocks and go buy glove stocks now :D
Stock
Stock
Stock: [SLVEST]: SOLARVEST HOLDINGS BERHAD
2021-02-02 18:10 | Report Abuse
https://www.sinchew.com.my/content/content_2421469.html